Clene Newsroom

Benchmark Maintains Buy on Clene, Lowers Price Target to $84

BenzingaNov 22 09:56 ET · Ratings

Clene Price Target Maintained With a $23.00/Share by D. Boral Capital

Dow JonesNov 13 17:37 ET · Ratings

Clene Is Maintained at Buy by D. Boral Capital

Dow JonesNov 13 17:37 ET · Ratings

Express News | Clene Inc. Files for Offering of up to 2.4 Mln Shares of Common Stock by Selling Securityholders- SEC Filing

ReutersNov 13 17:03 ET

Clene's Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic Developments

TipRanksNov 13 09:45 ET · Ratings

Clene Announces Q3 2024 Results and ALS Drug Progress

TipRanksNov 13 08:30 ET

Clene Q3 EPS $(1.22) Beats $(1.32) Estimate, Sales $87.00K Miss $90.00K Estimate

BenzingaNov 13 08:21 ET

Clene Expects Resources as of Sept 30 Combined With Offering Proceeds Will Be Sufficient to Fund Ops Into 1Q of 2025 >CLNN

Dow JonesNov 13 08:10 ET

8-K: CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

SECNov 13 08:07 ET

Clene Met With FDA on Nov 1 in Type C Meeting to Discuss Potential for Accelerated Approval Pathway in ALS >CLNN

Dow JonesNov 13 08:02 ET

Clene 3Q Loss/Shr $1.22 >CLNN

Dow JonesNov 13 08:01 ET

Clene 3Q Rev $87,000 >CLNN

Dow JonesNov 13 08:01 ET

Clene 3Q Loss $7.99M >CLNN

Dow JonesNov 13 08:01 ET

10-Q: Q3 2024 Earnings Report

SECNov 13 07:33 ET · Announcements

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

CleneNov 13 00:00 ET

H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31

Moomoo NewsOct 23 10:32 ET · Ratings

Strategic Advancements and Robust Trial Design Drive Buy Rating for Clene

TipRanksOct 23 10:15 ET · Ratings

Clene Unveils Phase 3 Trial Design at NEALS

TipRanksOct 23 08:28 ET

Benchmark Co. Sticks to Their Buy Rating for Clene (CLNN)

TipRanksOct 11 07:07 ET · Ratings

IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences

Yahoo FinanceOct 9 13:31 ET